Results 51 to 60 of about 273,364 (223)

Sero-epidemiology of human immunodeficiency virus, hepatitis B virus and hepatitis C virus: a cross-sectional survey in a rural setting of the West region of Cameroon

The Pan African Medical Journal, 2017
INTRODUCTION: human immunodeficiency Virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) are the three most common chronic viral infections worldwide, specifically in sub-Saharan Africa (SSA).
Jobert Richie Nansseu, Descartes Maxime Mbogning, Gwladys Chavely Monamele, Stive Fokam Tamoh, Hortense Kamga Gonsu, Charles Kouanfack, Yves Nathan Yanwou, Zacharie Sando   +7 more
doaj   +1 more source

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

New England Journal of Medicine, 2015
BACKGROUND As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.
Michael P. Curry, J. O’Leary, N. Bzowej, A. Muir, K. Korenblat, J. Fenkel, K. Reddy, E. Lawitz, S. Flamm, T. Schiano, L. Teperman, R. Fontana, EugeneR. Schiff, M. Fried, B. Doehle, D. An, J. McNally, A. Osinusi, D. Brainard, J. Mchutchison, Robert S. Brown, Michael Charlton   +21 more
semanticscholar   +1 more source

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Gastroenterology, 2017
BACKGROUND & AIMS Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir ...
Ira M. Jacobson, E. Lawitz, E. Gane, B. Willems, P. Ruane, R. Nahass, S. Borgia, S. Shafran, K. Workowski, Brian L. Pearlman, R. Hyland, L. Stamm, E. Svarovskaia, H. Dvory‐Sobol, Yanni Zhu, G. Subramanian, D. Brainard, J. Mchutchison, N. Bräu, T. Berg, K. Agarwal, B. Bhandari, Mitchell N. Davis, J. Feld, G. Dore, C. Stedman, A. Thompson, T. Asselah, S. Roberts, G. Foster   +29 more
semanticscholar   +1 more source

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

New England Journal of Medicine, 2017
BACKGROUND Chronic hepatitis C virus (HCV) infection is more prevalent among patients who have chronic kidney disease than among those who do not have the disease.
E. Gane, E. Lawitz, D. Pugatch, G. Papatheodoridis, N. Bräu, A. Brown, S. Pol, V. Leroy, M. Persico, Christophe Moreno, M. Colombo, E. Yoshida, D. Nelson, Christine A. Collins, Y. Lei, M. Kosloski, F. Mensa   +16 more
semanticscholar   +1 more source

The Hubble Catalog of Variables (HCV) [PDF]

, 2019
The Hubble Space Telescope (HST) has obtained multi-epoch observations providing the opportunity for a comprehensive variability search aiming to uncover new variables. We have therefore undertaken the task of creating a catalog of variable sources based on version 3 of the Hubble Source Catalog (HSC), which relies on publicly available images obtained
arxiv   +1 more source

Proceedings First Workshop on Horn Clauses for Verification and Synthesis [PDF]

EPTCS 169, 2014, 2014
This volume contains the proceedings of HCVS 2014, the First Workshop on Horn Clauses for Verification and Synthesis which was held on July 17, 2014 in Vienna, Austria as a satellite event of the Federated Logic Conference (FLoC) and part of the Vienna Summer of Logic (VSL 2014).
arxiv   +1 more source

Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice

Farmeconomia: Health Economics and Therapeutic Pathways, 2008
The current standard of care for the treatment of chronic hepatitis C virus (HCV) infection is combination therapy with Peg-interferon (IFN) alpha-2a or alpha-2b type plus ribavirin (RBV).
Luisa Cavalletto, Elisabetta Bernardinello, Giulio Diodati, Enzo Raise, Angelo Gatta, Liliana Chemello   +5 more
doaj   +1 more source

Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment [PDF]

, 2017
Hepatitis C virus (HCV) infection is endemic in people who inject drugs (PWID), with prevalence estimates above 60 percent for PWID in the United States. Previous modeling studies suggest that direct acting antiviral (DAA) treatment can lower overall prevalence in this population, but treatment is often delayed until the onset of advanced liver disease
arxiv   +1 more source

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Romanian Journal of Laboratory Medicine, 2017
Introduction. The past years have revolutionized the treatment of hepatitis C virus (HCV) infection, with high rates of sustained virologic response (SVR). Furthermore, liver fibrosis has recently been redefined as a dynamic, reversible process. Methods.
Nițescu Maria, Vâjâitu Cristina, Săndulescu Oana, Streinu-Cercel Adrian, Pițigoi Daniela, Preoțescu Liliana Lucia, Streinu-Cercel Anca   +6 more
doaj   +1 more source

ASSOCIATION BEETWEEN IL-28β POLYMORPHISMS AND EFFECTIVENESS OF CONCOMITANT THERAPY OF HIV INFECTION IN PATIENTS WITH HCV/HIV CO-INFECTION DURING THE ANTIVIRAL THERAPY

Инфекция и иммунитет, 2014
. The aim of the study was  to evaluate the associations between the polymorphism rs8099917 IL-28β and changing of HIV viral load and the effectiveness of high active antiretroviral therapy during the treatment of chronic hepatitis C in HIV-infected ...
E. S. Kovaleva
doaj   +1 more source